Tactogen

Tactogen is a San Francisco-based drug discovery company developing novel entactogen-based medicines derived from MDMA analogs to treat psychiatric conditions including PTSD and social anxiety. The company's core technology focuses on synthesizing and optimizing next-generation compounds that retain the therapeutic benefits of MDMA while refining safety and efficacy profiles. By targeting the entactogen class of psychoactive compounds, Tactogen aims to create medicines with improved tolerability and reduced adverse effects compared to existing treatments and their parent compounds.

As an early-stage company, Tactogen has secured $4 million in seed funding to advance its pipeline of MDMA analog candidates through preclinical development and regulatory pathways. The company operates within the rapidly expanding psychedelic therapeutics space, where there is growing clinical and regulatory momentum for entactogen and classical psychedelic-based treatments. With a focused pipeline strategy, Tactogen is positioned to contribute novel chemical entities to the emerging entactogen medicine category.

Tactogen matters to the neurotech industry because it represents the wave of precision drug development in the psychedelic therapeutics space, moving beyond natural compounds to rationally designed molecules with optimized therapeutic windows. The company's work on entactogens addresses a significant treatment gap for psychiatric conditions like PTSD and social anxiety, where current pharmacological options have limited efficacy and tolerability for many patients. By advancing safer, more effective entactogen-based medicines, Tactogen could help establish a new therapeutic class while expanding the clinical and commercial viability of psychedelic-derived treatments in mainstream psychiatry.